Glioblastoma-on-a-chip construction and therapeutic applications

Glioblastoma (GBM) is the most malignant type of primary intracranial tumor with a median overall survival only 14 months, very poor prognosis and recurrence rate 90%. It difficult to reflect complex structure function GBM microenvironment in vivo using traditional vitro models. GBM-on-a-chip platforms can integrate biological or chemical functional units into chip, mimicking functions cells. This technology has shown great potential for applications personalized precision medicine immunotherapy. In recent years, there have been efforts construct models based on microfluidics bioprinting. A number research teams begun use investigation progression mechanisms, drug candidates, therapeutic approaches. review first briefly discusses bioprinting technologies construction. Second, we classify non-surgical treatments pre-clinical three categories (chemotherapy, immunotherapy other therapies) focus each category. Last, demonstrate that organ-on-a-chip field still its initial stage provide future perspectives directions field.